Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimising pyrazinamide for the treatment of tuberculosis.
Zhang N, Savic RM, Boeree MJ, Peloquin CA, Weiner M, Heinrich N, Bliven-Sizemore E, Phillips PPJ, Hoelscher M, Whitworth W, Morlock G, Posey J, Stout JE, Mac Kenzie W, Aarnoutse R, Dooley KE; Tuberculosis Trials Consortium (TBTC) and Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) Networks. Zhang N, et al. Among authors: morlock g. Eur Respir J. 2021 Jul 20;58(1):2002013. doi: 10.1183/13993003.02013-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33542052 Free PMC article. Clinical Trial.
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE; Tuberculosis Trials Consortium. Dorman SE, et al. Am J Respir Crit Care Med. 2009 Aug 1;180(3):273-80. doi: 10.1164/rccm.200901-0078OC. Epub 2009 Apr 30. Am J Respir Crit Care Med. 2009. PMID: 19406981 Clinical Trial.
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.
Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. Campbell PJ, et al. Antimicrob Agents Chemother. 2011 May;55(5):2032-41. doi: 10.1128/AAC.01550-10. Epub 2011 Feb 7. Antimicrob Agents Chemother. 2011. PMID: 21300839 Free PMC article.
Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in MGIT.
Whitfield MG, Warren RM, Streicher EM, Sampson SL, Sirgel FA, van Helden PD, Mercante A, Willby M, Hughes K, Birkness K, Morlock G, van Rie A, Posey JE. Whitfield MG, et al. Among authors: morlock g. J Clin Microbiol. 2015 Nov;53(11):3633-5. doi: 10.1128/JCM.01001-15. Epub 2015 Aug 19. J Clin Microbiol. 2015. PMID: 26292310 Free PMC article.
Using Reduced Inoculum Densities of Mycobacterium tuberculosis in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation.
Morlock GP, Tyrrell FC, Baynham D, Escuyer VE, Green N, Kim Y, Longley-Olson PA, Parrish N, Pennington C, Tan D, Austin B, Posey JE. Morlock GP, et al. Tuberc Res Treat. 2017;2017:3748163. doi: 10.1155/2017/3748163. Epub 2017 Nov 8. Tuberc Res Treat. 2017. PMID: 29250443 Free PMC article.
Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.
Morlock GP, Crawford JT, Butler WR, Brim SE, Sikes D, Mazurek GH, Woodley CL, Cooksey RC. Morlock GP, et al. Antimicrob Agents Chemother. 2000 Sep;44(9):2291-5. doi: 10.1128/AAC.44.9.2291-2295.2000. Antimicrob Agents Chemother. 2000. PMID: 10952570 Free PMC article.
246 results